{"id":35800,"date":"2024-07-15T13:01:15","date_gmt":"2024-07-15T11:01:15","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=35800"},"modified":"2024-07-10T09:31:59","modified_gmt":"2024-07-10T07:31:59","slug":"35800","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/35800","title":{"rendered":"Antiinfektiva sind die h\u00e4ufigste Ursache f\u00fcr schwere arzneimittelbedingte Lebersch\u00e4digungen"},"content":{"rendered":"<p>Hepatotoxische Arzneimittelwirkungen (Drug-induced liver injury = DILI) sind der wichtigste Grund f\u00fcr ein akutes Leberversagen und f\u00fcr die Marktr\u00fccknahme eines zugelassenen Medikaments in Europa und den USA. Wir haben \u00fcber den Umgang mit dieser Problematik 2007 ausf\u00fchrlich am Beispiel orale Antikoagulanzien berichtet . Zur Inzidenz von DILI bei einzelnen Medikamenten ist wenig bekannt. H\u00e4ufig genannt [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hepatotoxische Arzneimittelwirkungen (Drug-induced liver injury = DILI) sind der wichtigste Grund f\u00fcr ein akutes Leberversagen und f\u00fcr die Marktr\u00fccknahme eines zugelassenen Medikaments in Europa und den USA. Wir haben \u00fcber den Umgang mit dieser Problematik 2007 ausf\u00fchrlich am Beispiel orale Antikoagulanzien berichtet . Zur Inzidenz von DILI bei einzelnen Medikamenten ist wenig bekannt. H\u00e4ufig genannt [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[462,343,6038,239,308,915,294,110,1692,2155,329,6037,646,4838,644,976,1699,6039,257,2593,117,1081,296,647,6040,382],"class_list":["post-35800","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amoxicillin-clavulansaeure","tag-antibiotika","tag-antiinfektiva","tag-azathioprin","tag-captopril","tag-chlorpromazin","tag-ciprofloxacin","tag-clarithromycin","tag-co-trimoxazol","tag-erlotinib","tag-fluconazol","tag-hepatotoxizitaet","tag-inh","tag-isoniacid","tag-ketoconazol","tag-lenalidomid","tag-levofloxacin","tag-livertox-arzneimittel","tag-medikamente","tag-mercaptopurin","tag-metronidazol","tag-moxifloxacin","tag-ofloxacin","tag-paracetamol","tag-prochlorperazin","tag-stavudin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/35800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=35800"}],"version-history":[{"count":1,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/35800\/revisions"}],"predecessor-version":[{"id":35801,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/35800\/revisions\/35801"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=35800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=35800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=35800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}